Latest News

Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.
Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– Breast Cancer

September 16th 2024

Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.
Breastfeeding Is Feasible Amid Endocrine Therapy Break in HR+ Breast Cancer

September 16th 2024

QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.
QOL, Pain Deterioration Improve With T-DXd in HER2-Low Breast Cancer

September 15th 2024

In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.
Hypofractionated Radiation Noninferior to Normofractionated Radiation in Early Breast Cancer

September 15th 2024

OS Increase Observed in Neoadjuvant Pembrolizumab Combo Plus Adjuvant Therapy in Early TNBC
OS Increase Observed in Neoadjuvant Pembrolizumab Combo Plus Adjuvant Therapy in Early TNBC

September 15th 2024